Program
ocrelizumab
Also written as “Ocrelizumab”, “CYB704” and “OCR SC”.
Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive · Multiple Sclerosis, Relapsing-Remitting · Lupus Nephritis, led by 5 companies.
Drug pageOcrelizumab: every studyMany companies study it; this page follows only the 42 they lead. All 56 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 3810 open or running | phase 4since Jul 5, 2018 | Feb 12, 2004 | Dec 31, 2027phase 3 · NCT05269004 |
| Celltrionits history only | 11 open or running | phase 3since May 9, 2023 | May 9, 2023 | Feb 2027phase 3 · NCT05906992 |
| Cinnagenits history only | 10 open or running | phase 3since Jun 27, 2021 | Jun 27, 2021 | none ahead |
| R-Pharmits history only | 11 open or running | phase 1since Apr 13, 2026 | Apr 13, 2026 | none ahead |
| Sandoz | 11 open or running | phase 3since Feb 19, 2025 | Feb 19, 2025 | none ahead |
Also a collaborator on its studies: PPD Development, LP, Laboratory Corporation of America and Roche Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sandoz only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 19, 2025First study: phase 3 study in Relapsing Multiple SclerosisFirst studyNCT06847724 · 183 enrolled · United States, Bosnia and Herzegovina, Bulgaria and more
Ahead
- Nov 3, 2026Primary completion: phase 3 study in Relapsing Multiple SclerosisNCT06847724
TargetBeta
“A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
The one study Sandoz leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06847724Relapsing Multiple Sclerosis · United States, Bosnia and Herzegovina, Bulgaria and more | 3 | Active, not recruiting | Nov 3, 2026 | 183 |
How it is read
Names in the registry
- “Ocrelizumab”, 36 entries
- “ocrelizumab”, 2 entries
- “CYB704”, 1 entry
- “OCR SC”, 1 entry
- “Ocrelizumab SC”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 18 studies
- Arthritis, Rheumatoid, 8 studies
- Multiple Sclerosis, Chronic Progressive, 7 studies
- Multiple Sclerosis, Relapsing-Remitting, 6 studies
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.